Contact

All Stories

  1. PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

    Article • Annals of Oncology, July 2026, Elsevier

    Dr Alessandro Russo

  2. Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices

    Article • Journal of Clinical Medicine, May 2026, MDPI AG

    Dr Alessandro Russo

  3. Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  4. Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  5. Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  6. Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  7. Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  8. Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  9. Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  10. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  11. Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  12. Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  13. Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  14. Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  15. Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  16. Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  17. Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  18. Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  19. Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  20. Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  21. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  22. Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • November 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  23. Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

    Article • Lung Cancer, November 2025, Elsevier

    Dr Alessandro Russo

  24. Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy

    Article • Lung Cancer, September 2025, Elsevier

    Dr Alessandro Russo

  25. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry

    Article • Journal for ImmunoTherapy of Cancer, September 2025, BMJ

    Dr Alessandro Russo

  26. Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients?

    Article • Diagnostics, August 2025, MDPI AG

    Dr Alessandro Russo

  27. Game-Set-MATCH: Liquid Biopsy Advances to the Next Round

    Article • Clinical Cancer Research, August 2025, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  28. Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL

    Article • Lung Cancer, August 2025, Elsevier

    Dr Alessandro Russo

  29. Expression of Membrane Targets for Therapeutics in RET-Positive Non–Small Cell Lung Cancer

    Article • JAMA Oncology, July 2025, American Medical Association (AMA)

    Dr Alessandro Russo

  30. Efficacy and Safety Analysis of Nab-Paclitaxel Treatment in Elderly Patients with HER-2 Negative Metastatic Breast Cancer: NEREIDE Study

    Article • Cancers, June 2025, MDPI AG

    Dr Alessandro Russo

  31. Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

    Article • Lung Cancer, June 2025, Elsevier

    Dr Alessandro Russo

  32. ADCs and TCE in SCLC Therapy: The Beginning of a New Era?

    Article • Current Oncology, April 2025, MDPI AG

    Dr Alessandro Russo

  33. Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group

    Article • Critical Reviews in Oncology/Hematology, April 2025, Elsevier

    Dr Alessandro Russo

  34. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

    Article • Journal for ImmunoTherapy of Cancer, February 2025, BMJ

    Dr Alessandro Russo

  35. The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer

    Article • Discover Oncology, January 2025, Springer Science + Business Media

    Dr Alessandro Russo

  36. Advanced-Stage Alk-Positive Non–Small-Cell Lung Cancer (Nsclc) Patients: Real-World Treatment Patterns and Outcomes from the Italian Biomarker Atlas Database

    Article • January 2025, Elsevier

    Dr Alessandro Russo

  37. The relevance of the reference range for EGFR testing in non-small cell lung cancer patients

    Article • Lung Cancer, December 2024, Elsevier

    Dr Alessandro Russo

  38. Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19

    Article • Journal of Extracellular Vesicles, November 2024, Wiley

    Dr Alessandro Russo

  39. Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting

    Article • Critical Reviews in Oncology/Hematology, October 2024, Elsevier

    Dr Alessandro Russo

  40. Facing an un-met need in lung cancer screening: The never smokers

    Article • Critical Reviews in Oncology/Hematology, October 2024, Elsevier

    Dr Alessandro Russo

  41. The Next Frontier for Colorectal Cancer Screening: Blood-Based Tests

    Article • Cancer Research, October 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  42. Data from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  43. Data from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  44. Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  45. Supplementary Figure S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  46. Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  47. Supplementary Figure S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  48. Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  49. Supplementary Figure S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  50. Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  51. Supplementary Figure S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  52. Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  53. Supplementary Figure S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  54. Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  55. Supplementary Figure S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  56. Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  57. Supplementary Figure S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  58. Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  59. Supplementary Figure S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  60. Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  61. Supplementary Methods S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  62. Supplementary Table S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  63. Supplementary Table S1 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  64. Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  65. Supplementary Table S10 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  66. Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  67. Supplementary Table S11 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  68. Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  69. Supplementary Table S2 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  70. Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  71. Supplementary Table S3 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  72. Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  73. Supplementary Table S4 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  74. Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  75. Supplementary Table S5 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  76. Supplementary Table S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  77. Supplementary Table S6 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  78. Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  79. Supplementary Table S7 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  80. Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  81. Supplementary Table S8 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  82. Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  83. Supplementary Table S9 from Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

    Article • September 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  84. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

    Article • Clinical Lung Cancer, September 2024, Elsevier

    Dr Alessandro Russo

  85. The Chemoimmunotherapy Revolution in Resectable NSCLC—The Times They Are A-Changin’

    Article • JAMA Oncology, May 2024, American Medical Association (AMA)

    Dr Alessandro Russo

  86. Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC

    Article • Cancer Research, March 2024, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  87. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC

    Article • Journal of Experimental & Clinical Cancer Research, March 2024, Springer Science + Business Media

    Dr Alessandro Russo

  88. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)

    Article • Annals of Oncology, March 2024, Elsevier

    Dr Alessandro Russo

  89. Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens

    Article • The Journal of Liquid Biopsy, March 2024, Elsevier

    Dr Alessandro Russo

  90. Navigating into a stormy sea: liquid biopsy enters peri-operative management in early-stage non-small cell lung cancer

    Article • Annals of Oncology, February 2024, Elsevier

    Dr Alessandro Russo

  91. Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment

    Article • JCO Precision Oncology, February 2024, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  92. LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?

    Article • Med, February 2024, Elsevier

    Dr Alessandro Russo

  93. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy

    Article • Frontiers in Immunology, January 2024, Frontiers

    Dr Alessandro Russo

  94. Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers

    Article • Cancer, January 2024, Wiley

    Dr Alessandro Russo

  95. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program

    Article • Lung Cancer, January 2024, Elsevier

    Dr Alessandro Russo

  96. Curvilinear Mesh Generation for the High-Order Virtual Element Method (VEM)

    Article • January 2024, Springer Science + Business Media

    Dr Alessandro Russo

  97. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

    Article • European Journal of Cancer, January 2024, Elsevier

    Dr Alessandro Russo

  98. In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer

    Article • Clinical Cancer Research, December 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  99. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations—a retrospective cohort study

    Article • Translational Lung Cancer Research, December 2023, AME Publishing Company

    Dr Alessandro Russo

  100. Abstract B145: Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors

    Article • Molecular Cancer Therapeutics, December 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  101. Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer

    Article • Biomarker Research, November 2023, Springer Science + Business Media

    Dr Alessandro Russo

  102. EP11.01-01 Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

  103. EP17.06-01 COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

  104. P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

  105. P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Alessandro Russo

  106. Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

    Article • Clinical Lung Cancer, November 2023, Elsevier

    Dr Alessandro Russo

  107. 1403P Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program

    Article • Annals of Oncology, October 2023, Elsevier

    Dr Alessandro Russo

  108. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy

    Article • Annals of Oncology, October 2023, Elsevier

    Dr Alessandro Russo

  109. 2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC

    Article • Annals of Oncology, October 2023, Elsevier

    Dr Alessandro Russo

  110. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group

    Article • Critical Reviews in Oncology/Hematology, October 2023, Elsevier

    Dr Alessandro Russo

  111. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations

    Article • Clinical Cancer Research, September 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  112. Brave new world of cfDNA-omics for early cancer detection

    Article • Journal for ImmunoTherapy of Cancer, September 2023, BMJ

    Dr Alessandro Russo

  113. Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  114. Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  115. Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  116. Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  117. Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  118. Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  119. Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  120. Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  121. Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  122. Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  123. Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  124. Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  125. Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  126. Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  127. Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  128. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  129. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  130. Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  131. Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  132. Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  133. Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  134. Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  135. Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  136. Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  137. Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  138. Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  139. Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  140. Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  141. Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  142. Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  143. Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  144. Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  145. Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  146. Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  147. Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  148. Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  149. Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  150. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  151. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  152. Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  153. Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • July 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  154. Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

    Article • La radiologia medica, June 2023, Springer Science + Business Media

    Dr Alessandro Russo

  155. Data from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  156. Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  157. Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  158. Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  159. Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  160. Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  161. Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  162. Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  163. Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  164. Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  165. Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  166. Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  167. Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  168. Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  169. Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  170. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  171. Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  172. Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  173. Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  174. Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  175. Supplementary Table S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  176. Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  177. Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  178. Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  179. Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  180. Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  181. Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  182. Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  183. Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  184. Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  185. Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  186. Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  187. Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  188. Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  189. Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  190. Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  191. Supplementary Table S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  192. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  193. Supplementary Table S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  194. Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  195. Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  196. Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction–Based Testing

    Article • Journal of Thoracic Oncology, June 2023, Elsevier

    Dr Alessandro Russo

  197. Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

    Article • Clinical Cancer Research, June 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  198. The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution?

    Article • EBioMedicine, June 2023, Elsevier

    Dr Alessandro Russo

  199. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

    Article • Journal of Thoracic Oncology, May 2023, Elsevier

    Dr Alessandro Russo

  200. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study

    Article • Targeted Oncology, April 2023, Springer Science + Business Media

    Dr Alessandro Russo

  201. Abstract 4329: Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy

    Article • Cancer Research, April 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  202. Moving Forward Liquid Biopsy in Early Liver Cancer Detection

    Article • Cancer Discovery, March 2023, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  203. Skipping or Not Skipping? That's the Question! An Algorithm to Classify Novel MET Exon 14 Variants in Non–Small-Cell Lung Cancer

    Article • JCO Precision Oncology, February 2023, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  204. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis

    Article • Frontiers in Endocrinology, January 2023, Frontiers

    Dr Alessandro Russo

  205. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?

    Article • International Journal of Molecular Sciences, December 2022, MDPI AG

    Dr Alessandro Russo

  206. Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer

    Article • Cancer, December 2022, Wiley

    Dr Alessandro Russo

  207. A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA

    Article • Translational Lung Cancer Research, October 2022, AME Publishing Company

    Dr Alessandro Russo

  208. Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions

    Article • European Journal of Cancer, October 2022, Elsevier

    Dr Alessandro Russo

  209. The evolving landscape of anatomic pathology

    Article • Critical Reviews in Oncology/Hematology, October 2022, Elsevier

    Dr Alessandro Russo

  210. The evolving role of liquid biopsy in lung cancer

    Article • Lung Cancer, October 2022, Elsevier

    Dr Alessandro Russo

  211. 1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC

    Article • Annals of Oncology, September 2022, Elsevier

    Dr Alessandro Russo

  212. 996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)

    Article • Annals of Oncology, September 2022, Elsevier

    Dr Alessandro Russo

  213. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)

    Article • Clinical Lung Cancer, September 2022, Elsevier

    Dr Alessandro Russo

  214. Expanding the Full Potential of Liquid Biopsies for Lung Cancer Patients

    Article • Cancer Research, August 2022, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  215. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

    Article • ESMO Open, August 2022, Elsevier

    Dr Alessandro Russo

  216. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

    Article • Lung Cancer, August 2022, Elsevier

    Dr Alessandro Russo

  217. Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives

    Article • Cancers, July 2022, MDPI AG

    Dr Alessandro Russo

  218. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question

    Article • Pharmaceutics, June 2022, MDPI AG

    Dr Alessandro Russo

  219. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

    Article • Journal of Experimental & Clinical Cancer Research, June 2022, Springer Science + Business Media

    Dr Alessandro Russo

  220. Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era

    Article • Critical Reviews in Oncology/Hematology, June 2022, Elsevier

    Dr Alessandro Russo

  221. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

    Article • ESMO Open, April 2022, Elsevier

    Dr Alessandro Russo

  222. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’

    Article • ESMO Open, April 2022, Elsevier

    Dr Alessandro Russo

  223. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

    Article • Journal of Thoracic Oncology, February 2022, Elsevier

    Dr Alessandro Russo

  224. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

    Article • Journal of Hematology & Oncology, January 2022, Springer Science + Business Media

    Dr Sebastiano Buti, Dr Alessandro Russo

  225. Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy

    Article • Therapeutic Advances in Medical Oncology, January 2022, SAGE Publications

    Dr Alessandro Russo

  226. KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

    Article • Therapeutic Advances in Respiratory Disease, January 2022, SAGE Publications

    Dr Alessandro Russo

  227. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics

    Article • Translational Oncology, January 2022, Elsevier

    Dr Alessandro Russo

  228. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

    Article • Theranostics, January 2022, Ivyspring International Publisher

    Dr Alessandro Russo

  229. A New Generation of Vaccines in the Age of Immunotherapy

    Article • Current Oncology Reports, November 2021, Springer Science + Business Media

    Dr Alessandro Russo

  230. 23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients

    Article • November 2021, BMJ

    Dr Alessandro Russo

  231. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer

    Article • Expert Review of Molecular Diagnostics, October 2021, Taylor & Francis

    Dr Alessandro Russo

  232. Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer

    Article • Cancers, October 2021, MDPI AG

    Dr Alessandro Russo

  233. Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

    Article • Nature Reviews Clinical Oncology, October 2021, Springer Science + Business Media

    Dr Alessandro Russo

  234. Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?

    Article • Expert Review of Anticancer Therapy, September 2021, Taylor & Francis

    Dr Alessandro Russo

  235. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

    Article • Nature Reviews Clinical Oncology, September 2021, Springer Science + Business Media

    Dr Alessandro Russo

  236. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

    Article • British Journal of Cancer, September 2021, Springer Science + Business Media

    Dr Alessandro Russo

  237. 966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy

    Article • Annals of Oncology, September 2021, Elsevier

    Dr Alessandro Russo

  238. Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib

    Article • Precision Cancer Medicine, September 2021, AME Publishing Company

    Dr Alessandro Russo

  239. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

    Article • Medical Oncology, August 2021, Springer Science + Business Media

    Dr Sebastiano Buti, Dr Alessandro Russo

  240. Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy

    Article • Translational Lung Cancer Research, July 2021, AME Publishing Company

    Dr Alessandro Russo

  241. Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review

    Article • Translational Lung Cancer Research, July 2021, AME Publishing Company

    Dr Alessandro Russo

  242. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

    Article • Journal of Translational Medicine, June 2021, Springer Science + Business Media

    Dr Sebastiano Buti, Dr Alessandro Russo

  243. Platelets Lead Morphological, Phenotypic and Functional Changes in Tumor Cells.

    Article • June 2021, Springer Science + Business Media

    Dr Alessandro Russo

  244. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

    Article • European Journal of Cancer, June 2021, Elsevier

    Dr Sebastiano Buti, Dr Alessandro Russo

  245. Dynamic levels of extracellular vesicle PD-L1 and complementary radiomics for the prediction of the response to immune checkpoint inhibitors in lung cancer patients.

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  246. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

    Article • European Journal of Cancer, May 2021, Elsevier

    Dr Sebastiano Buti, Dr Alessandro Russo

  247. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021

    Article • Critical Reviews in Oncology/Hematology, May 2021, Elsevier

    Dr Alessandro Russo

  248. Abstract PO-063: Extracellular vesicle miRNAs and autophagic CTCs: Predictive and prognostic biomarkers in radiotherapy treated NSCLC patients

    Article • Clinical Cancer Research, April 2021, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  249. Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective

    Article • Cancers, April 2021, MDPI AG

    Dr Alessandro Russo

  250. 117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients

    Article • Journal of Thoracic Oncology, April 2021, Elsevier

    Dr Alessandro Russo

  251. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

    Article • Journal for ImmunoTherapy of Cancer, April 2021, BMJ

    Dr Alessandro Russo

  252. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review

    Article • Oncology and Therapy, March 2021, Springer Science + Business Media

    Dr Alessandro Russo

  253. Radiomic Detection of EGFR Mutations in NSCLC

    Article • Cancer Research, February 2021, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  254. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

    Article • European Journal of Cancer, January 2021, Elsevier

    Dr Sebastiano Buti, Dr Alessandro Russo

  255. Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

    Article • January 2021, Springer Science + Business Media

    Dr Alessandro Russo

  256. Treatment Toxicity

    Article • January 2021, Springer Science + Business Media

    Dr Alessandro Russo

  257. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

    Article • Critical Reviews in Oncology/Hematology, December 2020, Elsevier

    Dr Alessandro Russo

  258. Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

    Article • Translational Lung Cancer Research, December 2020, AME Publishing Company

    Dr Alessandro Russo

  259. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

    Article • Journal for ImmunoTherapy of Cancer, November 2020, BMJ

    Dr Alessandro Russo

  260. Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy

    Article • Cancer Discovery, November 2020, American Association for Cancer Research (AACR)

    Dr Alessandro Russo, Dr Juan J Diaz-Mochon

  261. Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer

    Article • Journal of Thoracic Oncology, November 2020, Elsevier

    Dr Alessandro Russo

  262. Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America

    Article • JCO Global Oncology, November 2020, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  263. 31 Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients

    Article • November 2020, BMJ

    Dr Alessandro Russo

  264. Corrigendum to “Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)” [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]

    Article • Critical Reviews in Oncology/Hematology, October 2020, Elsevier

    Dr Alessandro Russo, Dr Juan J Diaz-Mochon

  265. Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report

    Article • Translational Lung Cancer Research, October 2020, AME Publishing Company

    Dr Alessandro Russo

  266. Targeted Therapies in Early Stage NSCLC: Hype or Hope?

    Article • International Journal of Molecular Sciences, August 2020, MDPI AG

    Dr Alessandro Russo

  267. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

    Article • European Journal of Cancer, July 2020, Elsevier

    Dr Alessandro Russo

  268. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)

    Article • Critical Reviews in Oncology/Hematology, July 2020, Elsevier

    Dr Alessandro Russo, Dr Juan J Diaz-Mochon

  269. NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC)

    Article • Precision Cancer Medicine, June 2020, AME Publishing Company

    Dr Alessandro Russo

  270. Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy

    Article • Cancer, May 2020, Wiley

    Dr Alessandro Russo

  271. Liquid biopsy for early stage lung cancer moves ever closer

    Article • Nature Reviews Clinical Oncology, May 2020, Springer Science + Business Media

    Dr Alessandro Russo

  272. HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target

    Article • Cancer Discovery, May 2020, American Association for Cancer Research (AACR)

    Dr Alessandro Russo

  273. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

    Article • Cancers, April 2020, MDPI AG

    Dr Alessandro Russo

  274. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

    Article • Current Oncology Reports, April 2020, Springer Science + Business Media

    Dr Alessandro Russo

  275. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study

    Article • April 2020, Cold Spring Harbor Laboratory Press

    Dr Alessandro Russo

  276. A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection

    Article • Cancers, March 2020, MDPI AG

    Dr Alessandro Russo

  277. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

    Article • Expert Opinion on Biological Therapy, February 2020, Taylor & Francis

    Dr Alessandro Russo

  278. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

    Article • Advances in Therapy, January 2020, Springer Science + Business Media

    Dr Alessandro Russo

  279. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

    Article • Cancers, January 2020, MDPI AG

    Dr Alessandro Russo

  280. Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten

    Article • Kompass Pneumologie, January 2020, Karger Publishers

    Dr Alessandro Russo

  281. Understanding EGFR heterogeneity in lung cancer

    Article • ESMO Open, January 2020, Elsevier

    Dr Alessandro Russo

  282. Immunotherapy in Lung Cancer: From a Minor God to the Olympus

    Article • January 2020, Springer Science + Business Media

    Dr Alessandro Russo

  283. RET fusions in solid tumors

    Article • Cancer Treatment Reviews, December 2019, Elsevier

    Dr Alessandro Russo

  284. 55P Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

    Article • Annals of Oncology, December 2019, Oxford University Press (OUP)

    Dr Alessandro Russo

  285. Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial

    Article • Translational Cancer Research, December 2019, AME Publishing Company

    Dr Alessandro Russo

  286. Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma

    Article • Cancers, November 2019, MDPI AG

    Dr Alessandro Russo

  287. O.01 Challenges of Interpreting NGS Liquid Biopsy (LB) Results in Advanced NSCLC: Are ESCAT and OncoKB Scales Reliable?

    Article • Journal of Thoracic Oncology, November 2019, Elsevier

    Dr Alessandro Russo

  288. Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

    Article • JCO Precision Oncology, November 2019, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  289. Liquid biopsy tracking of lung tumor evolutions over time

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO, francesco pepe

  290. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

    Article • Critical Reviews in Oncology/Hematology, October 2019, Elsevier

    Dr Alessandro Russo

  291. 1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable?

    Article • Annals of Oncology, October 2019, Oxford University Press (OUP)

    Dr Alessandro Russo

  292. P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Dr Alessandro Russo

  293. Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study

    Article • Cancers, July 2019, MDPI AG

    Dr Alessandro Russo

  294. How I treat ALK-positive non-small cell lung cancer

    Article • ESMO Open, July 2019, BMJ

    Dr Alessandro Russo

  295. Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  296. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

    Article • International Journal of Molecular Sciences, March 2019, MDPI AG

    Dr Alessandro Russo

  297. Immunotherapy use in patients with hiv and non-small-cell lung cancer: Current data

    Article • Journal of Immunotherapy and Precision Oncology, January 2019, Medknow

    Dr Alessandro Russo

  298. The changing scenario of 1 st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

    Article • Critical Reviews in Oncology/Hematology, October 2018, Elsevier

    Dr Alessandro Russo

  299. P1.04-28 Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study

    Article • Journal of Thoracic Oncology, October 2018, Elsevier

    Dr Alessandro Russo

  300. Acquired resistance in oncogene-addicted non-small-cell lung cancer

    Article • Future Oncology, June 2018, Future Medicine

    Dr Alessandro Russo

  301. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

    Article • Journal of Cellular Physiology, April 2018, Wiley

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  302. Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

    Article • BMC Cancer, January 2018, Springer Science + Business Media

    Dr Alessandro Russo

  303. E22Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

    Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

    Dr Alessandro Russo

  304. N2Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung

    Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

    Dr Alessandro Russo

  305. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

    Article • Critical Reviews in Oncology/Hematology, September 2017, Elsevier

    Dr Alessandro Russo

  306. Association between baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR), and platelet-to-lymphocyte ratio (PLR) and response to nivolumab (Nivo) in non-small cell lung cancer (NSCLC): A preliminary analysis.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  307. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer

    Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO

  308. Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

    Article • Oncotarget, January 2017, Impact Journals, LLC

    Dr Alessandro Russo

  309. Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Dr Alessandro Russo

  310. P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Dr Alessandro Russo

  311. Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site

    Article • Cancer Biology & Therapy, August 2016, Taylor & Francis

    Dr Alessandro Russo

  312. Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

    Article • OncoTargets and Therapy, July 2016, Dove Medical Press

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  313. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

    Article • Oncotarget, June 2016, Impact Journals, LLC

    MICHELE DE TURSI, Dr Alessandro Russo

  314. Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes.

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  315. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance

    Article • Expert Review of Anticancer Therapy, May 2016, Taylor & Francis

    Dr Alessandro Russo

  316. H44Epidermal Growth Factor Receptor mutational status predicts patterns of metastatic spread in treatment-naïve Adenocarcinomas of the lung

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  317. H47The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lung cancer patients: Findings from a retrospective analysis

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  318. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

    Article • Oncotarget, June 2015, Impact Journals, LLC

    Dr Alessandro Russo

  319. The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  320. 147P * DIFFERENT METASTATIC PATTERN ACCORDING TO THE EGFR MUTATIONAL STATUS IN A COHORT OF LUNG ADENOCARCINOMAS (ADCs): A SINGLE-INSTITUTION REPORT

    Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  321. 159P * IMPACT OF MAINTENANCE PEMETREXED IN THE MANAGEMENT OF NON-PROGRESSING MALIGNANT MESOTHELIOMAS AFTER STANDARD FIST-LINE CHEMOTHERAPY: A SINGLE INSTITUTION EXPERIENCE

    Article • Annals of Oncology, April 2015, Oxford University Press (OUP)

    Dr Alessandro Russo

  322. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

    Article • OncoTargets and Therapy, February 2015, Taylor & Francis

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  323. NSCLC and HER2: Between Lights and Shadows

    Article • Journal of Thoracic Oncology, December 2014, Elsevier

    Dr Alessandro Russo

  324. Impact of EGFR tyrosine kinase inhibitors in the management of brain metastases from EGFR-mutated and wild-type (WT) non-small cell lung cancer (NSCLC): A survival analysis.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Dr Alessandro Russo

  325. 47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

    Article • Lung Cancer, May 2013, Elsevier

    Dr Alessandro Russo